GF Fund Management’s Roivant Sciences ROIV Stock Holding History

GF Fund Management’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$503K	Sell	14,212 -1,408	-9%	-$41.6K	0.01%	216
2026 Q1	$433K	Buy	15,620 +1,952	+14%	+$50.1K	0.01%	228
2025 Q4	$297K	Sell	13,668 -1,024	-7%	-$20.2K	0.01%	256
2025 Q3	$222K	Sell	14,692 -3,949	-21%	-$48.9K	﹤0.01%	279
2025 Q2	$210K	Hold	18,641	–	–	﹤0.01%	314
2025 Q1	$188K	Buy	18,641 +3,356	+22%	+$36.3K	﹤0.01%	323
2024 Q4	$181K	Buy	+15,285	New	+$181K	﹤0.01%	298

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

GF Fund Management's ROIV Position: Q2 2026 in Review

GF Fund Management reduced its Roivant Sciences (ROIV) stake by 9% in Q2 2026, selling an estimated $41.6K and leaving 14,212 shares worth $503K. The position accounts for 0.01% of the portfolio, ranked #216.

GF Fund Management first reported a position in ROIV in Q4 2024 and has held it in 7 quarters since. 499 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

GF Fund Management held 14,212 shares of Roivant Sciences worth $503K as of Q2 2026.
GF Fund Management sold 1,408 Roivant Sciences shares in Q2 2026, an estimated $41.6K.
Roivant Sciences made up 0.01% of GF Fund Management's portfolio in Q2 2026, its #216 holding.
GF Fund Management first reported a position in Roivant Sciences in Q4 2024 and has held it in 7 quarters since.
499 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.